Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. Methods: This study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis, polycythemia vera and of healthy subjects, and analyzed correlations with JAK2 V617F status and clinical-hematological parameters. Results: The proinflammatory cytokine levels were increased in myeloproliferative neoplasm patients, and the presence of the JAK2 V617F mutation was associated with high IP-10 levels in primary myelofibrosis patients. Conclusions: Essential thrombocythemia, primary myelofibrosis, and polycythemia vera patients exhibited different patterns of cytokine production, as revealed by cytokine network correlations. Together, these findings suggest that augmented cytokine levels are associated with the physiopathology of myeloproliferative neoplasms.

MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

Background Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm whose pathogenesis is linked to the Philadelphia chromosome presence that generates the BCR–ABL1 fusion oncogene. Tyrosine kinase inhibitors (TKI) such as imatinib mesylate (IM) dramatically improved the treatment efficiency and survival of CML patients by targeting BCR–ABL tyrosine kinase. The disease shows three distinct clinical-laboratory stages: chronic phase, accelerated phase and blast crisis. Although patients in the chronic phase respond well to treatment, patients in the accelerated phase or blast crisis usually show therapy resistance and CML relapse. It is crucial, therefore, to identify biomarkers to predict CML genetic evolution and resistance to TKI therapy, considering not only the effects of genetic aberrations but also the role of epigenetic alterations during the disease. Although dysregulations in epigenetic modulators such as histone methyltrasnferases have already been described for some hematologic malignancies, to date very limited data is available for CML, especially when considering the lysine methyltransferase MLL2/KMT2D and MLL3/KMT2C. Methods Here we investigated the expression profile of both genes in CML patients in different stages of the disease, in patients showing different responses to therapy with IM and in non-neoplastic control samples. Imatinib sensitive and resistant CML cell lines were also used to investigate whether treatment with other tyrosine kinase inhibitors interfered in their expression. Results In patients, both methyltransferases were either upregulated or with basal expression level during the chronic phase compared to controls. Interestingly, MLL3/KMT2C and specially MLL2/KMT2D levels decreased during disease progression correlating with distinct clinical stages. Furthermore, MLL2/KMT2D was decreased in patients resistant to IM treatment. A rescue in the expression of both MLL genes was observed in KCL22S, a CML cell line sensitive to IM, after treatment with dasatinib or nilotinib which was associated with a higher rate of apoptosis, an enhanced expression of p21 (CDKN1A) and a concomitant decrease in the expression of CDK2, CDK4 and Cyclin B1 (CCNB1) in comparison to untreated KCL22S control or IM resistant KCL22R cell line, which suggests involvement of p53 regulated pathway. Conclusion Our results established a new association between MLL2/KMT2D and MLL3/KMT2C genes with CML and suggest that MLL2/KMT2D is associated with disease evolution and may be a potential marker to predict the development of therapy resistance

Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia

Progression to aggressive secondary acute myeloid leukaemia (sAML) poses a significant challenge in the management of myeloproliferative neoplasms (MPNs). Since the physiopathology of MPN is closely linked to the activation of interferon (IFN) signalling and that AML initiation and aggressiveness is driven by leukaemia stem cells (LSCs), we investigated these pathways in MPN to sAML progression. We found that high IFN signalling correlated with low LSC signalling in MPN and AML samples, while MPN progression and AML transformation were characterized by decreased IFN signalling and increased LSC signature. A high LSC to IFN expression ratio in MPN patients was associated with adverse clinical prognosis and higher colony forming potential. Moreover, treatment with hypomethylating agents (HMAs) activates the IFN signalling pathway in MPN cells by inducing a viral mimicry response. This response is characterized by double-stranded RNA (dsRNA) formation and MDA5/RIG-I activation. The HMA-induced IFN response leads to a reduction in LSC signature, resulting in decreased stemness. These findings reveal the frequent evasion of viral mimicry during MPN-to-sAML progression, establish the LSC-to-IFN expression ratio as a progression biomarker, and suggests that HMAs treatment can lead to haematological response in murine models by re-activating dsRNA-associated IFN signalling

Expression of Hippo pathway molecules in myeloproliferative neoplasms

As neoplasias mieloproliferativas (NMP) são doenças hematológicas caracterizadas pela proliferação aumentada e acúmulo de células mieloides maduras de uma ou mais séries hematopoéticas: granulocítica, eritrocítica, megacariocítica ou mastocítica. Os pacientes com NMP podem apresentar mutações como a JAK2V617F, MPL e CALR, cujas descrições foram fundamentais para o início da elucidação da fisiopatologia das NMP. As células neoplásicas das NMP apresentam resistência à apoptose e proliferação celular exacerbada. Sabe-se ainda que essas doenças são consideradas oncoinflamatórias e pré-leucêmicas. Apesar de todos esses conhecimentos sobre os mecanismos moleculares e celulares envolvidos na patogênese das NMP, não há até a presente data tratamentos eficazes que curam ou alteram a história natural de progressão dessas desordens para LMA. Pelo exposto, foi aqui investigada a potencial participação dos membros da via de sinalização Hippo na fisiopatologia das NMP BCR-ABL1 negativas mais frequentes, a policitemia vera (PV), trombocitemia essencial (TE) e mielofibrose primária (MF). A via de sinalização Hippo foi descrita como supressora de tumor e é uma das responsáveis pela regulação da proliferação, diferenciação e morte celular. Foi analisada, ainda nesse estudo, a correlação dos níveis de expressão dos genes da via Hippo com o perfil de citocinas plasmáticas dos pacientes com PV, TE e MF, a associação com o \"status mutacional\" e com a expressão dos genes que regulam a apoptose celular pela via intrínseca. Os principais achados nos pacientes com PV foram a diminuição da expressão dos genes supressores de tumor LATS2, MST1 e MST2 acompanhada pela presença de elevada concentração de citocinas pró-inflamatórias e fenótipo de resistência a apoptose. Na TE, os dados relevantes foram a detecção da diminuição da expressão dos genes supressores de tumor LATS1, LATS2 MST1 e SAV1, e o observação da relação entre alta expressão dos genes SAV1 e MOB1B e a mutação da CALR. Em MF destaca-se a redução da expressão dos genes SAV1 e TAZ da via de sinalização Hippo e do gene AURKB do ciclo celular. Em conclusão, os dados indicam que a diminuição da expressão dos genes supressores de tumor da via Hippo contribui para a fisiopatologia e para o fenótipo de resistência das células neoplásicas à apoptose das NMP.Myeloproliferative neoplasms (MPN) are hematological disorders characterized by increased proliferation of mature myeloids cells of one or more hematopoietic series: granulocytic, erythrocytic, megakaryocytic or mastocytic. Patients with MPN may present mutations such as JAK2V617F, MPL and CALR, which were essential descriptions for the beginning of pathophysiological elucidation of MPN. The NMP neoplastic cells show resistance to apoptosis and exacerbated cell proliferation. It is known that these entities are considered also oncoinflamatory and pre-leukaemic. Despite all this knowledge about the molecular and cellular mechanisms involved in the pathogenesis of MPN, there are no effective treatments that cure or alter the natural history of progression of these disorders to AML. For the above, a participatory potential of the Hippo signaling pathway members in the pathophysiology of the most frequent negative BCR-ABL1 MPN, the polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) were investigated. The Hippo signaling pathway has been described as tumor suppressor and is responsible for the regulation of proliferation, differentiation and cell death. The correlation analysis of the expression levels of the Hippo pathway genes with the plasma cytokine profile of patients with PV, ET and PMF, the association with the mutational status and the expression of the genes that regulate intrinsic cellular apoptosis were performed. The main findings in patients with PV were decreased expression of the tumor suppressor genes LATS2, MST1 and MST2 accompanied by the presence of high concentration of proinflammatory cytokines and phenotype of resistance to apoptosis. In ET, relevant data were the detection of decreased expression of the tumor suppressor genes LATS1, LATS2 MST1 and SAV1, and the observation of the relationship between high expression of the SAV1 and MOB1B genes and the mutation of the CALR. In PMF, stands out the reduction of the SAV1 and TAZ gene expression of the Hippo signaling pathway and the AURKB gene of the cell cycle. In conclusion, the data indicate that decreased expression of the tumor suppressor genes of the Hippo pathway contributes to the pathophysiology and neoplastic cell resistance phenotype to the apoptosis of MPN

Study of immunological biomarkers of functions of monocytes derived from HIV + patients

O vírus da imunodeficiência humana (HIV) é o responsável pela pandemia mundial da síndrome da imunodeficiência adquirida (AIDS). Uma vez infectado pelo HIV, o hospedeiro apresenta a forma aguda da doença, caracterizada por aumento da carga viral circulante, rápido declínio das células TCD4+ e ativação da resposta imune inata. Quando o HIV se estabelece no organismo, induz latência em algumas células e leva à cronicidade da infecção e nessa fase o principal alvo do HIV são as células T CD4+, observa-se então constante diminuição desta população, que tem como consequência a imunodeficiência, com desativação de outras células imunes, como os monócitos, macrófagos, células Natural Killer e neutrófilos. Portanto, há o favorecimento das infecções oportunistas por fungos, bactérias, parasitas e outros vírus, além do surgimento de neoplasias principais responsáveis pela morbidade e mortalidade relacionadas à AIDS. Para conter a destruição do sistema imune pelo vírus, inicia-se a terapia antirretroviral (TARV), sendo que o parâmetro disponível na clínica para início da terapia é a carga viral e contagem de células TCD4+. Neste sentido, investigamos se fatores relacionados à função e fenótipo de monócitos de pacientes HIV+ poderiam servir como biomarcadores da progressão da infecção. Para tanto, monócitos provenientes do sangue periférico de indivíduos HIV+, virgens ou não de tratamento e de indivíduos controle foram ou não infectadas in vitro com Salmonella Enteritidis. A capacidade fagocítica, a atividade microbicida, a produção de óxido nítrico (NO) e de citocinas foi avaliada e para avaliar a produção de espécies reativas do oxigênio (EROs), os monócitos foram ainda estimulados ou não com PMA. Concluímos que a infecção pelo HIV leva ao aumento da capacidade fagocítica de monócitos de homens quando comparados à mulheres nas mesmas condições, entretanto a infecção não altera funções como a atividade microbicida, produção de EROs ou NO, entretanto, o perfil de citocinas entre os grupos foi muito diferente, entretanto o uso de TARV é capaz de recuperar parcialmente as correlações formadas entre citocinas comparadas ao grupo controle. Desta forma uma bioassinatura funcional poderia ser descrita, tendo como base a produção diferencial de citocinas e quimiocinas, como IL-1?, IL-6 e IL-12p70.The human immunodeficiency virus (HIV) is the responsible for the acquired immunodeficiency syndrome (AIDS) global pandemic. Once infected with HIV, the host has an acute form of the disease, characterized by a very high circulating level of virus and a rapid decline in CD4+ T cells, and then, the activation of innate immune response. The HIV is established in the body, inducing latency in some cells and leads to chronic infection, phase which the main target of HIV are the CD4+ T cells, and then what we observe is the constant decline of this population, which brings the immunodeficiency as a consequence, characterized by the deactivation of other immune cells, such as monocytes, macrophages, natural killer and neutrophils. In this way, opportunistic infections by fungal, bacteria, parasites and others viuses in adition to the neoplasm are established, being the main responsible for the morbidity and mortality related to AIDS. To contain the immune system destruction by the virus, the antiretroviral therapy (HAART) can be initiated, and the clinical parameter available considered to the onset of therapy to is the viral load and CD4+ T cell counts. In this sense, we have investigated if the factors related to the function and phenotype of monocytes from HIV+ patients could serve as biomarkers of the progression of infection. To this end, monocytes from the peripheral blood of HIV+ patients treated or not with HAART and control subjects were infected or not in vitro with Salmonella Enteritidis. The phagocytic capacity, microbicidal activity, the production of nitric oxide (NO) or cytokines were evaluated and when monocytes were stimulated or not with PMA, the production of reactive oxygen species (ROS) was evaluated. We conclude that HIV infection leads to increased phagocytic ability of monocytes of men compared to women in the same conditions, however, the infection does not alter functions such as microbicidal activity and ROS and NO production, however, the cytokine profile between groups was very different, however the use of HAART is able to partially recover the correlations formed between cytokines compared to the control group. Thus a functional biosignature could be described based on the differential production of cytokines and chemokines such as IL-1?, IL-6 and IL-12p70

Cytotoxic and pro-apoptotic action of MjTX-I, a phospholipase A2 isolated from Bothrops moojeni snake venom, towards leukemic cells

Abstract Background Chronic myeloid leukemia (CML) is a BCR-ABL1 + myeloproliferative neoplasm marked by increased myeloproliferation and presence of leukemic cells resistant to apoptosis. The current first-line therapy for CML is administration of the tyrosine kinase inhibitors imatinib mesylate, dasatinib or nilotinib. Although effective to treat CML, some patients have become resistant to this therapy, leading to disease progression and death. Thus, the discovery of new compounds to improve CML therapy is still challenging. Here we addressed whether MjTX-I, a phospholipase A2 isolated from Bothrops moojeni snake venom, affects the viability of imatinib mesylate-resistant Bcr-Abl+ cell lines. Methods We examined the cytotoxic and pro-apoptotic effect of MjTX-I in K562-S and K562-R Bcr-Abl+ cells and in the non-tumor HEK-293 cell line and peripheral blood mononuclear cells, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and the hypotonic fluorescent solution methods, associated with detection of caspases 3, 8, and 9 activation and poly (ADP-ribose) polymerase (PARP) cleavage. We also analyzed the MjTX-I potential to modulate the expression of apoptosis-related genes in K562-S and K562-R cells. Results MjTX-I decreased the viability of K562-S and K562-R cells by 60 to 65%, without affecting the viability of the non-tumor cells, i.e. it exerted selective cytotoxicity towards Bcr-Abl+ cell lines. In leukemic cell lines, the toxin induced apoptosis, activated caspases 3, 8, and 9, cleaved PARP, downregulated expression of the anti-apoptotic gene BCL-2, and upregulated expression of the pro-apoptotic gene BAD. Conclusion The antitumor effect of MjTX-I is associated with its potential to induce apoptosis and cytotoxicity in Bcr-Abl positive cell lines sensitive and resistant to imatinib mesylate, indicating that MjTX-I is a promising candidate drug to upgrade the CML therapy

MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

Abstract Background Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm whose pathogenesis is linked to the Philadelphia chromosome presence that generates the BCR–ABL1 fusion oncogene. Tyrosine kinase inhibitors (TKI) such as imatinib mesylate (IM) dramatically improved the treatment efficiency and survival of CML patients by targeting BCR–ABL tyrosine kinase. The disease shows three distinct clinical-laboratory stages: chronic phase, accelerated phase and blast crisis. Although patients in the chronic phase respond well to treatment, patients in the accelerated phase or blast crisis usually show therapy resistance and CML relapse. It is crucial, therefore, to identify biomarkers to predict CML genetic evolution and resistance to TKI therapy, considering not only the effects of genetic aberrations but also the role of epigenetic alterations during the disease. Although dysregulations in epigenetic modulators such as histone methyltrasnferases have already been described for some hematologic malignancies, to date very limited data is available for CML, especially when considering the lysine methyltransferase MLL2/KMT2D and MLL3/KMT2C. Methods Here we investigated the expression profile of both genes in CML patients in different stages of the disease, in patients showing different responses to therapy with IM and in non-neoplastic control samples. Imatinib sensitive and resistant CML cell lines were also used to investigate whether treatment with other tyrosine kinase inhibitors interfered in their expression. Results In patients, both methyltransferases were either upregulated or with basal expression level during the chronic phase compared to controls. Interestingly, MLL3/KMT2C and specially MLL2/KMT2D levels decreased during disease progression correlating with distinct clinical stages. Furthermore, MLL2/KMT2D was decreased in patients resistant to IM treatment. A rescue in the expression of both MLL genes was observed in KCL22S, a CML cell line sensitive to IM, after treatment with dasatinib or nilotinib which was associated with a higher rate of apoptosis, an enhanced expression of p21 (CDKN1A) and a concomitant decrease in the expression of CDK2, CDK4 and Cyclin B1 (CCNB1) in comparison to untreated KCL22S control or IM resistant KCL22R cell line, which suggests involvement of p53 regulated pathway. Conclusion Our results established a new association between MLL2/KMT2D and MLL3/KMT2C genes with CML and suggest that MLL2/KMT2D is associated with disease evolution and may be a potential marker to predict the development of therapy resistance

Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.

Somatic mutations in the calreticulin (CALR) gene are associated with approximately 30% of essential thrombocythemia (ET) and primary myelofibrosis (PMF). CALR mutations, including the two most frequent 52 bp deletion (del52) and 5 bp insertion (ins5), induce a frameshift to the same alternative reading frame generating new C-terminal tails. In patients, del52 and ins5 induce two phenotypically distinct myeloproliferative neoplasms (MPNs). They are equally found in ET, but del52 is more frequent in PMF. We generated heterozygous and homozygous conditional inducible knock-in (KI) mice expressing a chimeric murine CALR del52 or ins5 with the human mutated C-terminal tail to investigate their pathogenic effects on hematopoiesis. Del52 induces greater phenotypic changes than ins5 including thrombocytosis, leukocytosis, splenomegaly, bone marrow hypocellularity, megakaryocytic lineage amplification, expansion and competitive advantage of the hematopoietic stem cell compartment. Homozygosity amplifies these features, suggesting a distinct contribution of homozygous clones to human MPNs. Moreover, homozygous del52 KI mice display features of a penetrant myelofibrosis-like disorder with extramedullary hematopoiesis linked to splenomegaly, megakaryocyte hyperplasia and the presence of reticulin fibers. Overall, modeling del52 and ins5 mutations in mice successfully recapitulates the differences in phenotypes observed in patients

Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients

Submitted by Nuzia Santos ([email protected]) on 2016-07-08T19:04:08Z No. of bitstreams: 1 ve_Espíndola_Milena_ Dysregulated_CPqRR_2015.PDF: 2923864 bytes, checksum: 446f6e96e03dda9a27eb6b0a5354e683 (MD5)Approved for entry into archive by Nuzia Santos ([email protected]) on 2016-07-08T19:23:26Z (GMT) No. of bitstreams: 1 ve_Espíndola_Milena_ Dysregulated_CPqRR_2015.PDF: 2923864 bytes, checksum: 446f6e96e03dda9a27eb6b0a5354e683 (MD5)Made available in DSpace on 2016-07-08T19:23:26Z (GMT). No. of bitstreams: 1 ve_Espíndola_Milena_ Dysregulated_CPqRR_2015.PDF: 2923864 bytes, checksum: 446f6e96e03dda9a27eb6b0a5354e683 (MD5) Previous issue date: 2015Made available in DSpace on 2016-07-22T13:23:08Z (GMT). No. of bitstreams: 3 ve_Espindola_Milena_ Dysregulated_CPqRR_2015.PDF.txt: 54746 bytes, checksum: 58738f3da9d5723ee829eddbd428183b (MD5) ve_Espindola_Milena_ Dysregulated_CPqRR_2015.PDF: 2923864 bytes, checksum: 446f6e96e03dda9a27eb6b0a5354e683 (MD5) license.txt: 2991 bytes, checksum: 5a560609d32a3863062d77ff32785d58 (MD5) Previous issue date: 2015Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.Universidade Federal de Uberlândia. Laboratório de Bioinformática e Análises Moleculares. Patos de Minas, MG, Brasil.Universidade Federal de Uberlândia. Laboratório de Bioinformática e Análises Moleculares. Patos de Minas, MG, Brasil.Universidade de São Paulo. Faculdade de Medicina de Ribeirão Preto. Ribeirão Preto, SP, Brasil.Fundação Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratório de Biomarcadores para Diagnostico e Monitoramento. Belo Horizonte, MG, Brasil.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.BACKGROUND: Successful highly active antiretroviral therapy (HAART) has changed the outcome of AIDS patients worldwide because the complete suppression of viremia improves health and prolongs life expectancy of HIV-1+ patients. However, little attention has been given to the immunological profile of patients under distinct HAART regimens. This work aimed to investigate the differences in the immunological pattern of HIV-1+ patients under the first- or second-line HAART in Brazil. METHODS: CD4+ T cell counts, Viral load, and plasma concentration of sCD14, sCD163, MCP-1, RANTES, IP-10, IL-1β, IL-6, TNF-α, IL-12, IFN-α, IFN-γ, IL-4, IL-5, and IL-10 were assessed for immunological characterization of the following clinical groups: Non-infected individuals (NI; n = 66), HIV-1+ untreated (HIV; n = 46), HIV-1+ treated with first-line HAART (HAART 1; n = 15); and HIV-1+ treated with second-line HAART (HAART 2; n = 15). RESULTS: We found that the immunological biosignature pattern of HAART 1 is similar to that of NI individuals, especially in patients presenting slow progression of the disease, while patients under HAART 2 remain in a moderate inflammatory state, which is similar to that of untreated HIV patients pattern. Network correlations revealed that differences in IP-10, TNF-α, IL-6, IFN-α, and IL-10 interactions were primordial in HIV disease and treatment. Heat map and decision tree analysis identified that IP-10>TNF-α>IFN-α were the best respective HAART segregation biomarkers. CONCLUSION: HIV patients in different HAART regimens develop distinct immunological biosignature, introducing a novel perspective into disease outcome and potential new therapies that consider HAART patients as a heterogeneous group

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. Methods: This study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis, polycythemia vera and of healthy subjects, and analyzed correlations with JAK2 V617F status and clinical-hematological parameters. Results: The proinflammatory cytokine levels were increased in myeloproliferative neoplasm patients, and the presence of the JAK2 V617F mutation was associated with high IP-10 levels in primary myelofibrosis patients. Conclusions: Essential thrombocythemia, primary myelofibrosis, and polycythemia vera patients exhibited different patterns of cytokine production, as revealed by cytokine network correlations. Together, these findings suggest that augmented cytokine levels are associated with the physiopathology of myeloproliferative neoplasms. Keywords: Ph-negative myeloproliferative neoplasms, Inflammation, Plasma cytokines, JAK2 V617